Viemed Healthcare Inc. (VMD) carries a Roarable Rating of C+ (Hold) with 69/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 6.59 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9
SEC XBRL FY 2025 (10-K): 4.4% FCF Margin ($11.9M FCF) & 57.5% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)
Even with a 69/100 (C+) score, VMD faces multiple-compression risk if 24.6x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Broader market pullbacks can still drag down strong stocks in the short run.
Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 55.0% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($9.23) or 200D SMA ($9.57) invalidates the momentum regime and cuts Target Base ($10.44) toward Bear Floor ($8.14).
Viemed Healthcare Inc. (VMD) slipped -0.40% to $9.95, trading at 59% of its 52-week range ($6.05 – $12.61). Solid 58% profit margin (13% return on capital), mixed timing at 25x P/E—hold if owned, no rush to chase.
Boston Scientific (BSX) delivered earnings and revenue surprises of 0.00% and +0.68%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Viemed Healthcare (NASDAQ:VMD) outlined its strategy to expand home-based respiratory care, diversify its revenue mix and maintain organic growth during a company presentation led by Chief Executive Officer Casey Hoyt an
LAFAYETTE, LA / ACCESS Newswire / October 22, 2026 / (the "Company" or "Viemed") (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and chronic disease management, today announced th
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +20.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on VMD today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for VMD. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Viemed Healthcare Inc. (VMD) ranks #103 by composite RQD confidence (69/100, grade C+) and #487 by equity capitalization ($379.0M). Within this direct 5-issuer industry benchmark cohort, VMD leads on earnings valuation at 24.6x trailing P/E, while CCEL leads on capital efficiency and profitability with 18.2% ROIC and — gross margin. PGNY currently holds the highest overall quantitative score in the immediate peer group at 77/100 (B+) compared with VMD at 69/100 (C+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| VMD
ACTIVE
Viemed Healthcare Inc. | C+ | 69/100 | 24.6x | 57.5% | 13.0% | -0.40% | $379.0M | Benchmark Subject |
| AGL agilon health inc. | E | 28/100 | — | — | -35.0% | -5.56% | $1.44B | /agl-vs-vmd → |
| PARK Park Dental Partners Inc. | D | 49/100 | — | — | — | -2.79% | $95.4M | /park-vs-vmd → |
| PGNY Progyny Inc. | B+ | 77/100 | 37.2x | 23.6% | 16.7% | +1.90% | $2.18B | /pgny-vs-vmd → |
| CCEL Cryo-Cell International Inc. | C | 64/100 | — | — | 18.2% | +1.17% | $41.8M | /ccel-vs-vmd → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Viemed Healthcare Inc. (VMD) reported GAAP revenue of $270.3M (+20.5% vs. FY2024 revenue of $224.3M , and +47.7% cumulative change since FY2023) , GAAP net income of $15.4M, operating cash flow of $51.9M, and free cash flow of $11.9M (+805.2% YoY). On the balance sheet, VMD closed FY2025 with $199.2M in total assets against $11.3M in total debt (Altman Z-Score: 6.59, Piotroski F-Score: 9/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $270.3M | $15.4M | $51.9M | $11.9M | $199.2M | $11.3M |
| FY2024 (FY) | 2024-12-31 | $224.3M | $11.4M | $39.1M | $1.3M | $177.1M | $3.6M |
| FY2023 (FY) | 2023-12-31 | $183.0M | $10.2M | $45.2M | $45.2M | — | — |
As of 2026-11-01, Viemed Healthcare Inc. (NASDAQ: VMD) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $9.95 (-0.40% 1D, market cap $379.0M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, VMD ranks #103 in composite RQD confidence.
Within the Health Care sector (Misc Health and Biotechnology Services), VMD carries a Roarable C+ (69/100 RQD), trailing P/E of 24.6x, gross margin of 57.5%, and ROIC of 13.0%. By comparison, AGL (agilon health inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $1.44B) and PARK (Park Dental Partners Inc.) posts a D grade (49/100 RQD, P/E N/A, ROIC —, cap $95.4M). Among the 5-stock peer group, VMD leads on earnings multiple (24.6x) while CCEL leads on capital efficiency (18.2% ROIC).
Per VMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001729149), Viemed Healthcare Inc. generated $270.3M in revenue (+20.5% YoY), $15.4M in net income, and $11.9M in free cash flow against $199.2M in total assets and $11.3M in total debt. Key quantitative strengths: Strong cash generator (58% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
VMD last traded at $9.95 (-0.40% on volume of 227,278 shares), positioning the stock +7.80% above its 50-day simple moving average ($9.23) and +3.97% above its 200-day simple moving average ($9.57). Across its 52-week range of $6.05 to $12.61, VMD sits at the 59.5% percentile with a 14-day RSI of 53.1 (NEUTRAL RANGE) and an implied next-earnings move of ±5.8% ($9.37 to $10.53).
Why VMD Stock slipped -0.40% Today — RQD Quant Desk Flash. Solid 58% profit margin (13% return on capital), mixed timing at 25x P/E—hold if owned, no rush to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.